Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05669833 · ClinicalTrials.gov registry record · Phase 3
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
A Phase 3 study of Psoriatic Arthritis, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 63
- Enrollment target
- 14
- Study locations
NCT05669833 is a Phase 3 study of Psoriatic Arthritis that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 63 participants, below the 852-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (93% lower). The trial reports 14 study locations across 10 states.
The verdict
NCT05669833, a Phase 3 study of Psoriatic Arthritis, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 63 participants
- Enrollment target
- 14
- Study locations
Study Summary
The trial is an open-label randomized study that will examine whether switching to a selective IL23 inhibitor (guselkumab) is more effective than switching to a second TNFi (golimumab) among patients with PsA who have an inadequate response to a TNFi.
Conditions Studied
Interventions
- DRUG Guselkumab
- DRUG Golimumab
Study Locations (14)
Florida
- Family Arthritis Center - Loxahatchee Groves
- Healing Rheumatology - Plant City
- Southwest Florida Rheumatology - Riverview
Ohio
- Cincy Arthritis - Blue Ash
- Southern Ohio Rheumatology - Wheelersburg
Texas
- Heritage Rheumatology and Arthritis Care - Colleyville
- Texas Arthritis Center - El Paso
Georgia
- Parris and Associates - Lilburn
Massachusetts
- University of Massachusetts Chan Medical School - Worcester
Nebraska
- University of Nebraska Medical Center - Omaha
New York
- New York University - New York
Pennsylvania
- Hospital at the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2023-07-14 |
| Est. Completion | 2026-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05669833
The ClinicalTrials.gov registry entry for NCT05669833 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 852-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (93% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriatic Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Guselkumab is the first listed.
NCT05669833 reports 14 study locations spanning 10 distinct geographic areas - top geographies include Florida, Ohio, Texas.
Frequently Asked Questions
What is clinical trial NCT05669833 about?
NCT05669833 is a clinical study titled "Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients". The trial is an open-label randomized study that will examine whether switching to a selective IL23 inhibitor (guselkumab) is more effective than switching to a second TNFi (golimumab) among patients with PsA who have an inadequate response to a TNFi.
What is the current status of trial NCT05669833?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 63 participants. The study started on 2023-07-14. Estimated completion is 2026-10.
What conditions does trial NCT05669833 study?
This clinical trial studies the following conditions: Psoriatic Arthritis.
What interventions are being tested in trial NCT05669833?
The interventions under investigation include: Guselkumab (DRUG), Golimumab (DRUG).
Who is sponsoring clinical trial NCT05669833?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05669833 being conducted?
This trial has 14 study locations across Florida, Georgia, Massachusetts, Nebraska, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriatic Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
RECRUITING · Phase 3
-
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
RECRUITING · Phase 3
-
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
RECRUITING · Phase 3
-
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
-
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.